[go: up one dir, main page]

PE20040172A1 - Imidazolinilmetil aralquilsulfonamidas - Google Patents

Imidazolinilmetil aralquilsulfonamidas

Info

Publication number
PE20040172A1
PE20040172A1 PE2003000388A PE2003000388A PE20040172A1 PE 20040172 A1 PE20040172 A1 PE 20040172A1 PE 2003000388 A PE2003000388 A PE 2003000388A PE 2003000388 A PE2003000388 A PE 2003000388A PE 20040172 A1 PE20040172 A1 PE 20040172A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
hydrogen
aralkylsulphonamides
methanosulfamide
Prior art date
Application number
PE2003000388A
Other languages
English (en)
Inventor
Michael Patrick Dillon
Xiaoming Zhang
Counde O'yang
Clara Jeou Jen Lin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20040172A1 publication Critical patent/PE20040172A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE IMIDAZOLINILMETIL ARALQUILSULFONAMIDAS DE FORMULA I DONDE R1 ES ALQUILO, NR7R8; R7 Y R8 SON INDEPENDIENTEMENTE HIDROGENO O ALQUILO; R2 ES HIDROGENO O ALQUILO; R3 A R6 SON INDEPENDIENTEMENTE HIDROGENO, ALQUILO, HALURO, ENTRE OTROS; R14 ES HIDROGENO, ALQUILO O -OR15; R15 ES HIDROGENO, ALQUILO INFERIOR O UN GRUPO PROTECTOR HIDROXI. SON COMPUESTOS PREFERIDOS:N-[4-(4,5-DIHIDRO-1H-IMIDAZOL-2-ILMETIL)-FENIL]-METANOSULFAMIDA,N-[4-(4,5-DIHIDRO-1H-IMIDAZOL-2-ILMETIL)-2-METOXI-FENIL]-METANOSULFAMIDA,N-[4-(4,5-DIHIDRO-1H-IMIDAZOL-2-ILMETIL)-2-METILO-FENIL]-METANOSULFAMIDA, ENTRE OTROS. EL COMPUESTO DE FORMULA I ES AGONISTA DEL RECEPTOR ADRENERGICO O1A/L Y ES UTIL PARA EL TRATAMIENTO DE INCONTINENCIA, DISFUNCION SEXUAL, CONGESTION NASAL
PE2003000388A 2002-04-23 2003-04-16 Imidazolinilmetil aralquilsulfonamidas PE20040172A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37470002P 2002-04-23 2002-04-23
US37877502P 2002-05-08 2002-05-08

Publications (1)

Publication Number Publication Date
PE20040172A1 true PE20040172A1 (es) 2004-04-08

Family

ID=29273005

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000388A PE20040172A1 (es) 2002-04-23 2003-04-16 Imidazolinilmetil aralquilsulfonamidas

Country Status (22)

Country Link
US (2) US6756395B2 (es)
EP (1) EP1501817A1 (es)
JP (1) JP4362379B2 (es)
KR (1) KR100696561B1 (es)
CN (1) CN1296365C (es)
AR (1) AR039319A1 (es)
AU (1) AU2003227623B2 (es)
BR (1) BR0309668A (es)
CA (1) CA2483345C (es)
HR (1) HRP20040951A2 (es)
IL (1) IL164676A0 (es)
MX (1) MXPA04010315A (es)
MY (1) MY139228A (es)
NO (1) NO20044531L (es)
NZ (1) NZ535823A (es)
PA (1) PA8571401A1 (es)
PE (1) PE20040172A1 (es)
PL (1) PL373322A1 (es)
RU (1) RU2318814C2 (es)
TW (1) TW200306807A (es)
UY (1) UY27770A1 (es)
WO (1) WO2003091236A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100696561B1 (ko) * 2002-04-23 2007-03-19 에프. 호프만-라 로슈 아게 이미다졸린일메틸 아르알킬설폰아마이드
EP1698611A4 (en) * 2003-12-26 2007-10-31 Daiichi Seiyaku Co PROCESS FOR PRODUCING A PHENYLACETIC ACID DERIVATIVE
MX2010007928A (es) * 2008-02-04 2010-08-09 Hoffmann La Roche Imidazolinilmetil aril sulfonamidas novedosas.
AU2009211506A1 (en) * 2008-02-04 2009-08-13 F. Hoffmann-La Roche Ag Novel imidazolinylmethyl aryl sulfonamides
CA2711871A1 (en) * 2008-02-04 2009-08-13 F. Hoffmann-La Roche Ag N-[3-bromo-2-chloro-4-(4, 5-dihydro-1h-imidazol-2-ylmethyl)-phenyl] -methanesulfoamide as alpha-1 a adrenergic partial agonist for the treatment of incontinence
US7799816B2 (en) 2008-02-04 2010-09-21 Roche Palo Alto Llc Imidazolinylmethyl aryl sulfonamide
MX2010008019A (es) * 2008-02-04 2010-08-10 Hoffmann La Roche Nuevas imidazolinilmetil aril sulfonamidas.
JP4168086B1 (ja) * 2008-04-16 2008-10-22 国立大学法人福井大学 イミダゾリン誘導体
CN103664845B (zh) * 2013-12-27 2016-02-10 湖南欧亚生物有限公司 一种Plk激酶抑制剂药物中间体7-氨基-2,3-二氢苯并呋喃-4-甲酸的制备方法
CN103853429B (zh) * 2014-03-14 2018-01-23 联想(北京)有限公司 信息处理方法、信息处理装置及电子设备
CN105693524A (zh) * 2014-11-28 2016-06-22 浙江省化工研究院有限公司 一种硝基化合物的制备方法
WO2021081292A1 (en) * 2019-10-25 2021-04-29 Curasen Therapeutics, Inc. METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH α1A-AR PARTIAL AGONISTS
KR20230058066A (ko) * 2020-08-27 2023-05-02 큐라센 테라퓨틱스, 인코포레이티드 α1A-아드레날린성 수용체 작용제 및 사용 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
AU3115471A (en) 1970-07-22 1973-01-18 Merck & Co Inc Chemical processes and products
HUT77357A (hu) * 1994-09-26 1998-03-30 Shionogi & Co. Ltd. AIDS-ellenes imidazolszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
TW405272B (en) 1997-06-25 2000-09-11 Sony Corp Method and apparatus for growth of a nitride III-V compound semiconductor
GB9910110D0 (en) * 1999-04-30 1999-06-30 Glaxo Group Ltd Chemical compounds
US6323231B1 (en) 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence
US6602897B2 (en) 2000-10-14 2003-08-05 Boehringer Ingelheim Pharma Kg m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence
US20020169193A1 (en) 2001-02-10 2002-11-14 Pascale Pouzet Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence
KR100696561B1 (ko) * 2002-04-23 2007-03-19 에프. 호프만-라 로슈 아게 이미다졸린일메틸 아르알킬설폰아마이드

Also Published As

Publication number Publication date
NO20044531L (no) 2004-11-19
HRP20040951A2 (hr) 2006-06-30
RU2004134326A (ru) 2006-01-27
EP1501817A1 (en) 2005-02-02
US6756395B2 (en) 2004-06-29
US20040214875A1 (en) 2004-10-28
TW200306807A (en) 2003-12-01
UY27770A1 (es) 2003-10-31
WO2003091236A1 (en) 2003-11-06
KR100696561B1 (ko) 2007-03-19
PA8571401A1 (es) 2004-02-07
CA2483345A1 (en) 2003-11-06
AR039319A1 (es) 2005-02-16
CA2483345C (en) 2010-12-21
US20030229130A1 (en) 2003-12-11
JP4362379B2 (ja) 2009-11-11
IL164676A0 (en) 2005-12-18
KR20040102151A (ko) 2004-12-03
AU2003227623B2 (en) 2010-05-20
NZ535823A (en) 2007-07-27
AU2003227623A1 (en) 2003-11-10
CN1646516A (zh) 2005-07-27
JP2005534628A (ja) 2005-11-17
MXPA04010315A (es) 2005-06-08
HK1080463A1 (en) 2006-04-28
MY139228A (en) 2009-08-28
PL373322A1 (en) 2005-08-22
BR0309668A (pt) 2005-03-01
CN1296365C (zh) 2007-01-24
RU2318814C2 (ru) 2008-03-10
US7407980B2 (en) 2008-08-05

Similar Documents

Publication Publication Date Title
PE20040172A1 (es) Imidazolinilmetil aralquilsulfonamidas
PE20010683A1 (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
PE85999A1 (es) Derivados de fenil y aminofenil-alquilsulfonamida y urea
PE20021094A1 (es) Derivados de ciclohexano-1,4-diamina sustituidos
PE20011030A1 (es) Combinaciones farmaceuticas que comprenden tegaserod y omeprazol
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
DK1173433T3 (da) Cyanopyrroler som progesteronreceptoragonister
RU2008130111A (ru) (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний
RU2323927C2 (ru) Производные 1-сульфонил-4-аминоалкоксииндола и фармацевтическая композиция, обладающая активностью модулятора 5-нт6 рецептора
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20030568A1 (es) Derivados de piperazina como antagonistas de receptores ccr1
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20050460A1 (es) COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
PE41796A1 (es) Compuesto activo en el receptor de serotonina 5-ht, util en el tratamiento de enfermedades del s.n.c.
PE20001648A1 (es) Derivados de 3-amino-3-arilpropan-1-ol y procedimientos de preparacion de los mismos
PE20000988A1 (es) Agonistas y antagonistas muscarinicos
PE20061049A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida como antagonistas del receptor de vanilloides tipo 1 (vr1)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal